Interleukin‐33 (IL‐33): A nuclear cytokine from the IL‐1 family

2017/12/16 by Corinne Cayrol, Jean‐Philippe Girard · 7 citations
Immunology and Microbiology · Medicine · #Eosinophilic Esophagitis #IL-33, ST2, and ILC Pathways #Immune Cell Function and Interaction

paper · pdf · doi:10.1111/imr.12619

openalex publication_date 2017/12/16 · openalex created_date 2018/01/05 · openalex updated_date 2026/07/29

Abstract

Summary Interleukin‐33 ( IL ‐33) is a tissue‐derived nuclear cytokine from the IL ‐1 family abundantly expressed in endothelial cells, epithelial cells and fibroblast‐like cells, both during homeostasis and inflammation. It functions as an alarm signal (alarmin) released upon cell injury or tissue damage to alert immune cells expressing the ST 2 receptor ( IL ‐1 RL 1). The major targets of IL ‐33 in vivo are tissue‐resident immune cells such as mast cells, group 2 innate lymphoid cells ( ILC 2s) and regulatory T cells (Tregs). Other cellular targets include T helper 2 (Th2) cells, eosinophils, basophils, dendritic cells, Th1 cells, CD 8 + T cells, NK cells, iNKT cells, B cells, neutrophils and macrophages. IL ‐33 is thus emerging as a crucial immune modulator with pleiotropic activities in type‐2, type‐1 and regulatory immune responses, and important roles in allergic, fibrotic, infectious, and chronic inflammatory diseases. The critical function of IL ‐33/ ST 2 signaling in allergic inflammation is illustrated by the fact that IL 33 and IL 1 RL 1 are among the most highly replicated susceptibility loci for asthma. In this review, we highlight 15 years of discoveries on IL ‐33 protein, including its molecular characteristics, nuclear localization, bioactive forms, cellular sources, mechanisms of release and regulation by proteases. Importantly, we emphasize data that have been validated using IL ‐33 ‐deficient cells.

Cited by

• Dermal White Adipose Tissue–Derived Il-33 Regulates Il-4/13 Expression in Myeloid Cells during Inflammation
• IL ‐33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways
• Mast cells and endothelial cells mediate interleukin-33 and ST2 responses in distal chronic obstructive pulmonary disease lungs
• Inflammatory responses following CRISPR modification of the nuclear localisation sequence in endogenous interleukin-1 alpha
• Molecular interactions and functions of IL-32
• ‘Layered immunity’ and the ‘neonatal window of opportunity’ – timed succession of non‐redundant phases to establish mucosal host–microbial homeostasis after birth
• The IL-33/ST2 signaling axis drives pathogenesis in acute SARS-CoV-2 infection

Related

• IL ‐33: biological properties, functions, and roles in airway disease
• Negative regulation of human IL-33 in endothelium during allergic airway inflammation
• IL-33 Amplifies the Polarization of Alternatively Activated Macrophages That Contribute to Airway Inflammation
• IL ‐33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways
• The role of interleukin-33 in chronic rhinosinusitis